Combenefit statistics

Tool stats & trends

Looking to identify usage trends or leading experts?


Combenefit specifications


Unique identifier OMICS_11597
Name Combenefit
Alternative name Combinations Benefit
Software type Package/Module
Interface Command line interface, Graphical user interface
Restrictions to use None
Operating system Unix/Linux, Mac OS, Windows
Programming languages MATLAB
License MIT License
Computer skills Advanced
Version 2.021
Stability Stable
Maintained Yes


No version available



  • person_outline Giovanni Y. Di Veroli

Publication for Combinations Benefit

Combenefit citations


In silico drug combination discovery for personalized cancer therapy

BMC Syst Biol
PMCID: 5861486
PMID: 29560824
DOI: 10.1186/s12918-018-0546-1

[…] onalized drug combination synergy prediction pipeline and Fig.  shows how our pipeline works with an example data. Synergy in the pipeline is defined as a synergy score quantified using a tool called Combenefit []. We used genomic information such as gene expression, mutation, and copy number variation data of cell lines from various unbiased cancer types, and target information of cancer drugs to […]


Hepatocellular carcinoma targeted nanoparticles for cancer therapy

PMCID: 5741373
PMID: 29207071
DOI: 10.3892/ijo.2017.4205

[…] ion combination, and viability was assessed after 3 days of treatment using the MTT-based assay. The cytotoxicity of each drug and of their combinations was assessed by drug response matrix using the Combenefit software (). Loewe synergy score and HSA synergy score were calculated and plotting by SynergyFinder software (). […]


Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology

Nat Commun
PMCID: 5681654
PMID: 29127277
DOI: 10.1038/s41467-017-01582-5
call_split See protocol

[…] xpressed as a percentage of proliferation compared to untreated cells. The experiments were performed in triplicates and data are presented as the mean ± s.d. Drug synergy effects were analysed using Combenefit (Cancer Research Cambridge Institute), a software tool that enables the visualisation, analysis and quantification of drug combination effects. The data from combination treatments were pro […]


Vemurafenib resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E

PMCID: 5689570
PMID: 29156680
DOI: 10.18632/oncotarget.21262

[…] centrations maintaining a constant final concentration at 2% DMSO for optimal solubility (more details are reported in the ). Combined treatments of vemurafenib plus palbociclib were calculated using Combenefit script [] by MATLAB R2017a applying Bliss, Highest Single Agent (HSA), and Loewe methods in order to assess drug synergy and antagonism. Cells were treated for 48 hours in the presence of 0 […]


Modulating Protein Protein Interactions of the Mitotic Polo like Kinases to Target Mutant KRAS

Cell Chem Biol
PMCID: 5563081
PMID: 28807782
DOI: 10.1016/j.chembiol.2017.07.009

[…] ormed as follows: 96-well plates were treated with a dilution series of each drug in an 8 × 8 checkerboard pattern of combinations (). After SRB staining to obtain the growth inhibition data, we used Combenefit software to identify synergistic drug combinations, focusing on BLISS independence (). The single-agent inhibition values were used to calculate a drug combination surface under the assumpt […]


Identification of deubiquitinase targets of isothiocyanates using SILAC assisted quantitative mass spectrometry

PMCID: 5584250
PMID: 28881649
DOI: 10.18632/oncotarget.17261

[…] concentrations of either 12 or 25 μM PEITC and 25 μM (7.5 μg/mL) cisplatin (CI values of 0.79 and 0.82, respectively; Figure ). The interaction between cisplatin and PEITC was further analyzed using Combenefit [] to assess three classic drug interaction models, Loewe, Bliss, and the Highest Single Agent (HSA) model. All three models showed strong synergistic effects for the combination of PEITC ( […]


Looking to check out a full list of citations?

Combenefit institution(s)
CRUK Cambridge Institute, University of Cambridge, UK; Early Clinical Development, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, UK; Bioinformatics, Oncology Innovative Medicines, AstraZeneca, Cambridge, UK
Combenefit funding source(s)
This work has been supported by the Cancer Research UK grant C14303/A17197.

Combenefit reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review Combenefit